GERN($4.40) strong buy
Wadegarret portfolio has been loading lately. There is only one other company(Brystol Myers) in the entire world that has a drug for low risk MDS, and GERN has the better drug that treats 4 times as many patients. I looked at the Q1 10Q for Brystol Myers, and their drug Reblozy to treat low risk MDS, did $364M, so a pace of $1.2B/year. In the ADCOM on March 14, at least a dozen doctors from around the world, many who were Hematologists, said GERNs drug was badly needed. I believe GERN will get bought out within 6 months for around $10.
